Clinical Trial Update: Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating efalizumab for moderate to severe psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Raptiva (efalizumab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Moderate to Severe Psoriasis | Phase 3 | Status: COMPLETED